Candel Therapeutics (CADL) Analyst & Key Data

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

9

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$10.55

Median Target+89.66%

$20.00

Potential upside vs current price

DCF Value-79.09%

$2.20

Potential downside vs current price

Current Stock Price

$10.55

Median Target+89.66%

$20.00

Potential upside vs current price

DCF Value-79.09%

$2.20

Potential downside vs current price

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

9

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$10.55

Median Target+89.66%

$20.00

Potential upside vs current price

DCF Value-79.09%

$2.20

Potential downside vs current price

Current Stock Price

$10.55

Median Target+89.66%

$20.00

Potential upside vs current price

DCF Value-79.09%

$2.20

Potential downside vs current price

Candel Therapeutics, Inc.